Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson's Biggest Drug Rivals

By Dan Carroll - Apr 7, 2013 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We take a look into the competitors of J&J's top-selling drugs

When it comes to health care companies, there's no bigger name than the largest firm in the business: Johnson & Johnson (JNJ -1.86%).

What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all. That can make it tough on investors trying to understand this highly diversified company, however: With so many parts, what do you need to keep an eye on? To get a grip on this colossus of the health care sector, let's take a look at Johnson & Johnson's top competitors to its pharmaceutical division and best-selling drugs.

Battling the blockbusters
Let's start by diving into the biggest competition for Johnson & Johnson's biggest drug: Anti-inflammatory therapy Remicade, which made more than $6 billion for the company last year and grew revenues by nearly 12% year-over-year. Remicade's got many uses from treating rheumatoid arthritis to Crohn's disease and more, and its usefulness has made it a standout drug for years.

The immunology market's a big one, however, and Remicade's toughest rivals are bestsellers by their own rights. AbbVie's (ABBV -1.52%) anti-inflammatory medication Humira, used to treat several indications including the aforementioned rheumatoid arthritis, ranks as one of the best-selling drugs in history. Humira pulled in bank-breaking sales of $9.3 billion last year, and with a few more years of patent protection still left, AbbVie's blockbuster will continue to be one of Johnson & Johnson's biggest challengers.

Right up there with Humira is Amgen (AMGN -0.57%) and Pfizer's (PFE -1.83%) Enbrel. The immunology drug and titan in the rheumatology field has years of patent protection left and, like Humira, outsold Remicade last year. Enbrel recorded more than $8 billion in sales last year, although Amgen and Pfizer split the proceeds: The latter controls the drug's sales outside of the U.S. and Canada. Given this drug's patent exclusivity will last the better part of the next decade, however, J&J investors will have to keep a close eye on this Remicade rival.

However, J&J's introduced its own new immunology competitor to fight back against Enbrel and Humira's power. Psoriasis drug Stelara has already reached blockbuster status and saw outstanding sales growth of nearly 39% last year. J&J filed for approval of the drug in treating psoriatic arthritis in the EU and U.S.; if it wins those approvals, Stelara will have a new source of serious revenue that will threaten Enbrel and Humira's positions atop the pharmaceutical world.

Beyond immunology
Johnson & Johnson's pharmaceuticals branch is more than just immunology, however -- and other drugs bring in more and more rivals to watch.

Remicade might be safe from patent expiration, but some of J&J's other drugs aren't so lucky. Sales of the Levaquin and Floxin family of infectious disease drugs, which had recorded blockbuster sales as recently as 2010, have been hammered by generic competition to the point of less than $100 million in 2012 revenue. Neuroscience drug Concerta has also seen its revenue chipped away by generic competitors; while the drug still managed to exceed $1 billion in revenue last year, it saw a 15% sales decline year-over-year and is poised to dip below that level in 2013.

Prostate cancer pill Zytiga, which has seen excellent growth early in its post-approval life, ran into competition last year after Medivation's (MDVN) rival pill Xtandi received FDA approval. Analysts peg Xtandi's peak sales at between $1 billion and $2 billion, and while Zytiga's almost hit the blockbuster mark already, there should be a good battle between these two in the prostate cancer treatment market in the future.

What about Johnson & Johnson's great new hope -- recently approved diabetes drug Invokana? The treatment picked up FDA approval just days ago, but Invokana enters a highly competitive field looking to take advantage of the rapidly growing diabetes market. Merck's (MRK -0.97%) Januvia and Janumet are the big kids on the diabetes block, and the two drugs combined to pull in 14% of Merck's 2012 pharmaceutical revenue by themselves.

However, Bristol-Myers Squibb's (BMY -1.53%) and AstraZeneca's (AZN -3.53%) diabetes drug Forxiga is a more direct rival to Invokana. The FDA rejected Forxiga last year, but the drug's chances in the U.S . could be improved after the EU granted approval for Forxiga in November. It's too early to say how the battle between Forxiga and Invokana will play out, but with the diabetes market continuing to heat up due to rising rates of obesity, there's no doubt that this will be a prime-time fight.

There are tough competitors across the board for Johnson & Johnson's best-selling pharmaceuticals. From big pharma's biggest players such as Pfizer and Merck to small-time biotech companies like Medivation, J&J will have to keep pressing forward in order to stay ahead of its rivals. Fortunately, this company's size, experience, and power across the entire health care industry make Johnson & Johnson one health care stock you can count on.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$175.50 (-1.86%) $-3.32
Medivation, Inc. Stock Quote
Medivation, Inc.
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.40 (-1.83%) $0.94
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.10 (-0.97%) $0.90
Amgen Inc. Stock Quote
Amgen Inc.
$243.96 (-0.57%) $-1.39
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$63.32 (-3.53%) $-2.32
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$77.02 (-1.53%) $-1.20
AbbVie Inc. Stock Quote
AbbVie Inc.
$152.43 (-1.52%) $-2.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.